RESUMEN
Lyophilized bacterial lysates, which actively stimulate the immune response, are widely used as vaccines or 'biological response modifiers' in subjects with recurrent bacterial respiratory infections. Since vaccines are indicated in the absence or in the presence of a weak constitutive immune response activity, a better knowledge on the 'naturally' occurring antibacterial immune response at the oropharingeal level should be helpful. A study was, therefore, designed to quantify the presence of salivary IgA directed against surface antigens bacteria frequently involved in the pathogenesis of upper respiratory tract infections: Klebsiella pneumoniae (KP), Staphylococcus aureus (SA), Streptococcus pyogenes (SPy), Morraxella catarrhalis (MC), Haemophylus influenzae (HI), and Streptococcus pnumoniae (SPn). In 34 volunteers (21 adults and 13 children), salivary fluid was collected and the presence of microorganism-specific IgA antibodies evaluated by a novel enzyme immuno-assay. In the whole population only 29 and 24% of subjects had IgA directed, respectively, to KP and SA, while the immune-response against other microbes was detectable in a small population ranging from 12 to 15% of all subjects studied. We found higher proportions of individuals with strain specific salivary IgA in the adult than in the pediatric population for all the microorganism evaluated. In addition, in children, the only strain inducing a significant production of specific IgA at oropharingeal level was KP. Interestingly, only ten out of 21 adults and two out 13 children have at least one significantly high antibody titer against one of the bacteria evaluated. Nevertheless, when a group of healthy donors was treated with a polyvalent mechanical bacterial lysate (Ismigen t.), the large majority developed a specific immune-response in the salivary fluid. These results are thus consistent with the good features of the novel enzyme-immunoassay and with a poor frequency of naturally induced specific anti-microbe antibodies in children and in adults despite the presence on recurrent respiratory infections in their clinical history.
Asunto(s)
Bacterias/inmunología , Inmunidad Innata , Inmunoglobulina A Secretora/inmunología , Infecciones del Sistema Respiratorio/inmunología , Saliva/química , Adulto , Factores de Edad , Niño , Femenino , Haemophilus influenzae/inmunología , Humanos , Técnicas para Inmunoenzimas/métodos , Inmunoglobulina A Secretora/análisis , Klebsiella pneumoniae/inmunología , Masculino , Infecciones del Sistema Respiratorio/microbiología , Staphylococcus aureus/inmunología , Streptococcus pneumoniae/inmunología , Streptococcus pyogenes/inmunologíaRESUMEN
OBJECTIVE: The aim of this double-blind, randomized, multicenter study was to compare the efficacy of betahistine dihydrochloride (BH) and flunarizine (FL) using the Dizziness Handicap Inventory (DHI), a validated self-assessment questionnaire that has not previously been used in a clinical trial to evaluate antivertigo drugs. MATERIAL AND METHODS: Patients with recurrent vertigo of peripheral vestibular origin and who were severely handicapped by vertigo were randomized to an 8-week course of treatment with oral BH 48 mg daily or oral FL 10 mg daily. The efficacy endpoints were the total DHI score and the physical, functional and emotional subscores. RESULTS: Fifty-two patients completed the study. After 8 weeks of treatment the mean total DHI score and the physical subscore were significantly lower in the BH group compared to the FL group (7.5 and 3.6 points, respectively). The mean total DHI score as well as the three subscores decreased significantly after 4 and 8 weeks in both treatment groups. CONCLUSION: This study showed that at 8 weeks BH is significantly more effective than FL in terms of improving the total DHI score and the physical subscore. It was also established that the DHI is a useful and reliable method for evaluating the efficacy of antivertigo drugs.
Asunto(s)
Betahistina/uso terapéutico , Flunarizina/uso terapéutico , Agonistas de los Receptores Histamínicos/uso terapéutico , Vasodilatadores/uso terapéutico , Vértigo/tratamiento farmacológico , Adulto , Anciano , Betahistina/administración & dosificación , Método Doble Ciego , Esquema de Medicación , Femenino , Flunarizina/administración & dosificación , Agonistas de los Receptores Histamínicos/administración & dosificación , Humanos , Masculino , Enfermedad de Meniere/complicaciones , Enfermedad de Meniere/etiología , Persona de Mediana Edad , Recurrencia , Encuestas y Cuestionarios , Resultado del Tratamiento , Vasodilatadores/administración & dosificación , Vértigo/fisiopatología , Vértigo/psicologíaRESUMEN
There is a clear connection between upper and lower airways. Allergic rhinitis may affect asthma by worsening natural history. Airways share similarities and differences such as: epidemiology, anatomy, physiology, immunopathology, and treatment. In asthmatic patients non-responder to conventional treatment, therapeutic success may be achieved only by recognizing and treating co-existent upper airways disorders. New therapeutical strategies should be based on a rational (i.e. considering the pathophysiology of the single patient) use of: antihistamines, antileukotrienes, and corticosteroids.
Asunto(s)
Bronquios/fisiopatología , Rinitis Alérgica Perenne/fisiopatología , Asma/complicaciones , Asma/fisiopatología , Niño , Humanos , Incidencia , Prevalencia , Rinitis Alérgica Perenne/complicaciones , Rinitis Alérgica Perenne/epidemiologíaRESUMEN
BACKGROUND: The small airways may play an important role in the clinical manifestations of asthma. Forced expiratory flow between 25% and 75% (FEF25%-75%) has been proposed as an approximate measure of the caliber of distal airways. Bronchial hyperreactivity (BHR) is a feature of asthma. OBJECTIVE: To evaluate the possible role of FEF25%-75% as a predictor of BHR in allergic patients with asthma and rhinitis. METHODS: A total of 726 patients (mean +/- SD age, 24.7 +/- 6.3 years) were evaluated. Spirometry and methacholine bronchial challenge were evaluated in all the participants. RESULTS: A difference between forced expiratory volume in 1 second and FEF25%-75% greater than 20 or a ratio between these variables greater than 1.24 discriminates between patients with no response to a mild response to methacholine vs patients with a moderate-to-severe response with high sensitivity (P < .001). CONCLUSION: This study highlights the possible role of FEF25%-75% in predicting BHR in allergic individuals with airway disorders.
Asunto(s)
Hiperreactividad Bronquial/fisiopatología , Hipersensibilidad/fisiopatología , Flujo Espiratorio Medio Máximo , Adulto , Biomarcadores , Hiperreactividad Bronquial/inmunología , Pruebas de Provocación Bronquial , Broncoconstrictores/farmacología , Estudios Transversales , Femenino , Volumen Espiratorio Forzado , Humanos , Hipersensibilidad/inmunología , Masculino , Cloruro de Metacolina/farmacología , Curva ROCRESUMEN
BACKGROUND: Allergic rhinitis may be associated with asthma. Forced expiratory flow between 25 and 75% of vital capacity (FEF2575) is a measure of small airways narrowing. The aim of this study was to evaluate whether patients with seasonal allergic rhinitis (SAR) without symptoms of asthma might, nevertheless, have airways obstruction both in and out of the pollen season. METHODS: Fifty patients (mean age, 23.7+/-4.9 years) with SAR were evaluated both during and outside the pollen season. All of them had moderate-severe grade of nasal obstruction. Total symptom score, rhinomanometry, nasal lavage, nasal scraping, spirometry, and methacholine (MCH) bronchial challenge were assessed in all subjects. RESULTS: Although data on forced vital capacity and response to MCH were similar in and out of the pollen season, all other parameters were markedly different. The major finding of the study was that FEF25-75 was significantly associated with nearly all of the parameters considered, including bronchial hyperreactivity, with Pearson R ranging from 31 to 75% and differences in mean FEF25-75 ranging between 14.5 and 16.5% of predicted. The more significant association was with nasal airflow in the pollen season (R = 82.8%; p < 0.001). A significant association persisted for all parameters while controlling for season. CONCLUSION: This study highlights the link between upper and lower airways and the role of FEF25-75 as an early marker of bronchial impairment in those patients with SAR alone.
Asunto(s)
Broncoconstricción/fisiología , Rinitis Alérgica Estacional/fisiopatología , Adulto , Progresión de la Enfermedad , Humanos , Masculino , Flujo Espiratorio Medio Máximo/fisiología , Pronóstico , Índice de Severidad de la Enfermedad , Capacidad Vital/fisiologíaRESUMEN
BACKGROUND: Rhinomanometry measures nasal airflow that is frequently impaired in allergic rhinitis. Decongestion tests consist of spraying an intranasal vasoconstrictor drug to evaluate the reversibility of nasal airflow limitation. The aim of this study was to evaluate the decongestion test in patients with seasonal allergic rhinitis (SAR) caused by pollen sensitization, perennial allergic rhinitis (PAR) caused by sensitization to perennial allergens only, or mixed allergic rhinitis (MAR) caused by sensitization to both allergens. METHODS: One hundred twenty-three subjects (112 men and 11 women, mean age, 22.9 +/- 5.7 years) were studied; 40 subjects had PAR, 43 subjects had MAR, and 40 subjects had SAR. Total symptom score (including: nasal itching, sneezing, rhinorrhea, and nasal obstruction) was assessed. Rhinomanometry and decongestion tests were performed in all subjects. RESULTS: Nasal symptom severity was superimposable in the three groups (p was not significant). After decongestion tests, an increase of nasal airflow and a decrease of nasal resistance was shown in PAR (p < 0.01), MAR (p < 0.001), and SAR subjects (p < 0.001). The intergroup analysis showed that SAR patients had less reversibility than PAR (p < 0.01). CONCLUSION: This study provides the first evidence of the different response to decongestion tests, taking into consideration the causal allergens.
Asunto(s)
Descongestionantes Nasales , Ventilación Pulmonar , Rinitis Alérgica Perenne/diagnóstico , Rinitis Alérgica Perenne/fisiopatología , Rinitis Alérgica Estacional/diagnóstico , Rinitis Alérgica Estacional/fisiopatología , Administración Intranasal , Adulto , Resistencia de las Vías Respiratorias/efectos de los fármacos , Alérgenos/efectos adversos , Femenino , Humanos , Hipertrofia/diagnóstico , Hipertrofia/epidemiología , Hipertrofia/fisiopatología , Masculino , Descongestionantes Nasales/administración & dosificación , Polen/efectos adversos , Prevalencia , Estudios Prospectivos , Ventilación Pulmonar/efectos de los fármacos , Rinitis Alérgica Perenne/etiología , Rinitis Alérgica Estacional/etiología , Rinomanometría , Pruebas Cutáneas , Cornetes Nasales/patologíaRESUMEN
BACKGROUND: Chronic rhinosinusitis is frequently associated with asthma. A Th2 cytokine pattern has been recently reported in chronic rhinosinusitis in asthmatic children. OBJECTIVE: To evaluate the effects of treating concomitant chronic rhinosinusitis on respiratory symptoms and function and immunopathological parameters in asthmatic children. METHODS: Eighteen children with moderate asthma (age range, 5 to 12 years) poorly controlled by high doses of inhaled corticosteroids and chronic rhinosinusitis were evaluated for symptoms, spirometry, and inflammation at baseline, after treatment, and 1 month after suspension of treatment. All of the children were treated with a combination of amoxicillin and clavulanate (20 mg/kg twice daily) and fluticasone propionate aqueous nasal spray (100 microg/d) for 14 days. A short course of oral corticosteroids was also prescribed (deflazacort, 1 mg/kg daily for 2 days, 0.5 mg/kg daily for 4 days, and 0.25 mg/kg daily for 4 days). Rhinosinusal lavage for cytokine measurements and a nasal scraping for cytologic analysis were performed in all patients before and after medical treatment. RESULTS: A negative endoscopy result was demonstrated in 15 children after treatment. Symptoms and respiratory function significantly improved after treatment and 1 month later; 8 children had intermittent asthma and 10 had mild asthma. A significant reduction of inflammatory cell numbers was detected in all asthmatic children. Interleukin 4 levels significantly decreased (P < 0.001), whereas interferon-y levels increased (P < 0.001). CONCLUSION: Treatment of chronic rhinosinusitis is able to improve symptoms and respiratory function in asthmatic children, reducing inflammatory cells and reversing the cytokine pattern from a Th2 toward a Th1 profile.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Androstadienos/uso terapéutico , Antiinflamatorios/uso terapéutico , Asma/complicaciones , Quimioterapia Combinada/uso terapéutico , Rinitis Alérgica Perenne/complicaciones , Sinusitis/complicaciones , Asma/tratamiento farmacológico , Niño , Preescolar , Endoscopía , Femenino , Fluticasona , Volumen Espiratorio Forzado , Humanos , Interferón gamma/metabolismo , Interleucina-4/metabolismo , Masculino , Neutrófilos/metabolismo , Pregnenodionas/uso terapéutico , Rinitis Alérgica Perenne/tratamiento farmacológico , Sinusitis/tratamiento farmacológicoRESUMEN
A Th2 cytokine pattern has recently been reported both in allergic and nonallergic chronic rhinosinusitis in asthmatic children. The aim of the study was to evaluate the cytokine pattern in chronic rhinosinusitis in allergic and nonallergic asthmatic children before and after medical treatment. Thirty asthmatic children were evaluated, 18 males and 12 females (mean age 9.1 years). Sixteen were allergic and 14 were nonallergic. All children were asthmatic and suffered from chronic rhinosinusitis, whose diagnosis was confirmed by endoscopy. All of them were treated with amoxicilline-clavulanate (20 mg/kg b.i.d.) and fluticasone propionate aqueous nasal spray (100 microg daily) for 14 days; a short course of oral corticosteroid was also prescribed (deflazacort 1 mg/kg daily for 2 days, 0.5 mg/kg daily for 4 days and 0.25 mg/kg daily for 4 days). Rhinosinusal lavage and nasal cytology were performed in all subjects before and after medical treatment. IL4 and IFNgamma were measured by immunoassay and inflammatory cells were counted by conventional staining. Thirteen allergic children and 12 nonallergic children showed a negative endoscopy after the treatment. Allergic subjects showed a significant decrease of IL4 (p = 0.0002) and a significant increase of IFNgamma (p = 0.03) after the treatment. Nonallergic children showed a significant decrease of IL4 (p = 0.0007) and a nonsignificant increase of IFNgamma. A significant reduction of the inflammatory infiltrate was detected in all asthmatic children (p < 0.05). This study confirms a Th2 polarization in chronic rhinosinusitis both in allergic and nonallergic asthmatic children. Moreover, the medical treatment of chronic rhinosinusitis reversed the cytokine pattern from a Th2 towards a Th1 profile both in allergic and nonallergic children.